

NYSHEX technology council meetings, and other discussions relevant to the management of NYSHEX in addition to participating in NYSHEX Board meetings. The Amended would also remove Ocean Network Express Pte. Ltd. (ONE) and add Mediterranean Shipping Company SA.

*Proposed Effective Date:* 10/30/2023.

*Location:* <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/2064>.

Dated: September 20, 2023.

**Carl Savoy,**

*Federal Register Alternate Liaison Officer,  
Federal Maritime Commission.*

[FR Doc. 2023–20674 Filed 9–22–23; 8:45 am]

**BILLING CODE 6730–02–P**

## FEDERAL MARITIME COMMISSION

[Docket No. 23–05]

**Rahal International Inc., Complainant v. Hapag-Lloyd AG, Hapag-Lloyd (America), LLC, and Hapag-Lloyd USA, LLC, Respondents and Third-Party Complainants v. Maher Terminals, LLC, GCT New York LP, and GCT Bayonne LP, Third-Party Respondents; Notice of Filing of Third-Party Complaint; Correction**

**AGENCY:** Federal Maritime Commission.

**ACTION:** Notice; correction.

**SUMMARY:** On September 8, 2023, the Federal Maritime Commission (FMC) published a document in the **Federal Register** of September 15, 2023, concerning a third-party complaint filed in Docket No. 23–05. This document incorrectly designated Hapag-Lloyd USA, LLC as a Third-Party Complainant.

**FOR FURTHER INFORMATION CONTACT:** Amy Strauss, Acting Secretary, (202) 523–5725 or [secretary@fmc.gov](mailto:secretary@fmc.gov).

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of September 15, 2023, on page 63575:

1. in the first column remove the document title and replace with the following: Rahal International Inc., Complainant v. Hapag-Lloyd AG, Hapag-Lloyd (America), LLC, and

Hapag-Lloyd USA, LLC, Respondents and Hapag-Lloyd AG and Hapag-Lloyd (America), LLC, Third-Party Complainants v. Maher Terminals, LLC, GCT New York LP, and GCT Bayonne LP, Third-Party Respondents; Notice of Filing of Third-Party Complaint

2. in the second column, both times it appears, remove “Hapag-Lloyd AG, Hapag-Lloyd (America), LLC, and Hapag-Lloyd USA, LLC” and replace with the following: Hapag-Lloyd AG and Hapag-Lloyd (America), LLC

3. in the second column, remove the following paragraph: Respondent and Third-Party Complainant Hapag-Lloyd USA, LLC is a United States subsidiary and agent of Hapag-Lloyd AG with its office located in Atlanta, Georgia.

**Carl Savoy,**

*Federal Register Alternate Liaison Officer,  
Federal Maritime Commission.*

[FR Doc. 2023–20642 Filed 9–22–23; 8:45 am]

**BILLING CODE 6730–02–P**

## FEDERAL TRADE COMMISSION

[File No. P222100]

**Horseracing Integrity and Safety Authority Anti-Doping and Medication Control Rule Modification**

**AGENCY:** Federal Trade Commission

**ACTION:** Notice of Horseracing Integrity and Safety Authority (HISA) proposed rule modification; request for public comment.

**SUMMARY:** As required by the Horseracing Integrity and Safety Act of 2020, the Federal Trade Commission (“FTC” or “Commission”) publishes a proposed rule modification related to the equine Anti-Doping and Medication Control Program of the Horseracing Integrity and Safety Authority (“HISA” or the “Authority”). Specifically, the proposed rule modification would designate iron dextran as a banned substance and thereby prohibit its use. This publication contains the Authority’s proposed rule’s text and explanation, and it seeks public comment on whether the Commission should approve the proposed rule.

**DATES:** The Commission must approve or disapprove the proposed modification on or before November 24, 2023. If approved, the proposed rule modification would be effective immediately. Comments must be filed on or before October 10, 2023.

**ADDRESSES:** Interested parties may file a comment online or on paper by following the instructions in the Request for Comment part of the **SUPPLEMENTARY INFORMATION** section. Write “HISA Anti-Doping and Medication Control Rule Modification” on your comment and file your comment online at <https://www.regulations.gov> by following the instructions on the web-based form. If you prefer to file your comment on paper, mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, Suite CC–5610 (Annex H), Washington, DC 20580.

**FOR FURTHER INFORMATION CONTACT:** John H. Seesel (202–326–2702), Associate General Counsel, Office of the General Counsel, Federal Trade Commission, 600 Pennsylvania Avenue NW, Washington, DC 20580.

**SUPPLEMENTARY INFORMATION:** On July 8, 2023, pursuant to section 3053(a) of the Horseracing Integrity and Safety Act of 2020 (“Act”) <sup>1</sup> and FTC Rule 1.142,<sup>2</sup> the Horseracing Integrity and Safety Authority (“HISA” or the “Authority”) filed with the Commission a proposed modification of the Authority’s anti-doping rules to include iron dextran as a banned substance. Sections I and II below set forth the Authority’s proposal. The Commission is publishing this document to solicit comments on the proposed rule modification from interested persons.

The proposed modification would insert the following row for Iron Dextran into the “Technical Document—Prohibited Substances” appendix to the Prohibited List (Rule Series 4000), between the row for Irbesartan and the row for Isoaminile.

<sup>1</sup> 15 U.S.C. 3051 through 3060.

<sup>2</sup> 16 CFR 1.142.